Boundless Bio, Inc.
Developing ecDNA-directed therapies for intractable oncogene amplified cancers.
BOLD | NDAQ
Overview
Corporate Details
- ISIN(s):
- US10170A1007
- LEI:
- Country:
- United States of America
- Address:
- 10955 ALEXANDRIA WAY, 92121 SAN DIEGO
- Website:
- https://boundlessbio.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Boundless Bio, Inc. is a clinical-stage, next-generation precision oncology company developing novel therapies for patients with intractable oncogene amplified cancers. The company is pioneering the development of ecDNA-directed therapies (ecDTx), which target extrachromosomal DNA (ecDNA), a root cause of oncogene amplification in over 17% of solid tumors. By exploiting this unique vulnerability in cancer cells, Boundless Bio is advancing a robust pipeline of medicines to address a significant unmet need where current targeted and immunotherapies have proven largely ineffective. The company positions itself as a leader in the field of ecDNA-based cancer therapeutics.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Boundless Bio, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Boundless Bio, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Boundless Bio, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
/other/Diamyd_Medical_AB_publ-logo.png){kind=logo}
